CIEDON INC
MIDDLETOWN, CT 06457-1740
Visibility Score
24
Capabilities Narrative
Non-small cell lung cancer (NSCLC) is the third most common cancer in the US, yet current standard-of-care is insufficient because the five-year survival rate is still around 20%. Abnormal calcium regulation has previously been suggested as an important driver for malignancy. Therefore, inhibition o...
NAICS Codes
| Code | Description | Primary |
|---|---|---|
| 541714 | Research and Development in Biotechnology (except Nanobiotechnology) |
Keywords
Drug development, Oncology
Contact Information
Business Details
- UEI
- DK5EUDM8X776
- CAGE Code
- 9E7Q7
- Year Established
- 2022
- Legal Structure
- Corporation
- Congressional District
- 01